Milmiga (Liraglutide)

Liraglutide, the active ingredient in Milmiga, is a GLP-1 receptor agonist presented as a subcutaneous injection for subcutaneous use. It treats type 2 diabetes mellitus and aids weight management in obesity. GNH USA supplies Milmiga as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Liraglutide is used in the management of metabolic disorders that involve glucose regulation and body weight.

- Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c levels. - Obesity/weight management: promotes satiety and facilitates weight loss in adults with obesity. - Cardiovascular risk reduction: lowers major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.

Liraglutide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: transient, often diminishes with continued therapy. - Vomiting: may accompany nausea, especially during dose escalation. - Diarrhea: usually mild and self‑limiting. - Constipation: occasional, manageable with diet. - Headache: mild to moderate intensity. - Injection site reactions: erythema, pruritus, or swelling. - Decreased appetite: contributes to weight loss.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate discontinuation. - Gallbladder disease: cholelithiasis or cholecystitis. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas. - Renal impairment: acute kidney injury in susceptible individuals. - Anaphylactic reactions: rare but potentially life‑threatening.

Before initiating liraglutide therapy, several safety considerations should be reviewed.

- Renal function: monitor creatinine and eGFR, adjust use in severe impairment. - Thyroid C‑cell tumors: contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2. - Pancreatitis: discontinue if signs of acute pancreatitis appear. - Hypoglycemia risk: educate patients when used with insulin or sulfonylureas. - Pregnancy and lactation: safety unknown; avoid unless benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Liraglutide can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Insulin: combined use increases risk of severe hypoglycemia. - Sulfonylureas: additive hypoglycemic effect, may require dose reduction. - Medications that delay gastric emptying: may exacerbate gastrointestinal side effects.

Moderate Interactions (Monitor Closely): - Warfarin: monitor INR as liraglutide may affect anticoagulation control. - Oral contraceptives: possible reduced effectiveness, consider alternative methods. - Beta‑blockers: may mask hypoglycemia symptoms, requiring closer glucose monitoring.